NCT07228195

SGLT2i Therapy in Islet Transplantation (SIT)

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.

Conditions

• Partial Islet Function
• TPIAT
• Diabetes

Interventions

Type	Name	Description
DRUG	Empagliflozin 25 MG Oral Tablet	Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.
DRUG	Empagliflozin 10 MG Oral Tablet [Jardiance]	Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.

Timeline

• Start date: 2026-05-15
• Primary completion: 2028-12-01
• Completion: 2028-12-01
• First posted: 2025-11-14
• Last updated: 2026-03-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study